Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of cytokine-induced killer cells in early period after autologous hematopoietic stem cell transplantation
KCT0004024Phase 2Completed
- Sponsor
- Seoul St. Mary's Hospital
- Start
- Mar 2021
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of unmodified CIK in lymphoma, sponsored by Seoul St. Mary's Hospital. Started Mar 2021; status: completed.
02
Drugs
unmodified CIK
03
Conditions
lymphoma
Beyond the preview
Go deeper on KCT0004024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004024.